Teladoc Health, Inc. (TDOC) Q3 2025 10-Q Quarterly Report
Filed: Oct 30, 2025Period ending Sep 30, 2025
Health Care
Services-Offices & Clinics of Doctors of MedicineSEC EDGAR Teladoc Health, Inc. (TDOC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Teladoc Health, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New operational risk: CFO Mala Murthy resignation effective Nov 21, 2025, CEO Charles Divita to serve as interim principal financial officer
- • Financial risk update: Credit Agreement dated July 17, 2025, with JPMorgan Chase Bank as administrative agent executed July 23, 2025
- • Regulatory/compliance risk: Adoption of Rule 10b5-1 trading plans by President and Board member for up to 10,000 shares sales and purchases through late 2025
- • Market risk: Leadership transition may impact near-term strategic execution and investor confidence
- • No new currency or liquidity risks specifically disclosed in this filing
Get deeper insights on Teladoc Health, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.